Considering offers from two MM investment banks: MTS and Leerink. Any insight into how they are doing (recent activity), quality of MD hires, relative strength in verticals (services, biopharma, etc.)?
Anything is appreciated.
| +299 | I Snuck Into UBS Office And Took A Shit On The Floor | 28 | 5h |
| +287 | TPH V.S. Mizuho [HOU] | 36 | 1d |
| +243 | Why leave restructuring for M&A? | 30 | 5h |
| +228 | Best Power/Renewables/Energy Teams? | 38 | 3h |
| +223 | Houston 2026 Oil & Gas Investment Banking Rankings | 51 | 1h |
| +186 | Centerview HC group falling off? | 30 | 4h |
| +183 | Actual EB List | 27 | 14h |
| +172 | Incoming TPH Analysts Larping as PWP on LinkedIn | 23 | 57m |
| +154 | Shame on you Evercore - SA 28 | 41 | 2d |
| +138 | Predicted 1Q 2027 Story - UBS IB blames Outlook Outage for Down Quarter | 24 | 5m |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
^following
Did a coffee chat with someone from MTS years ago, sounded like you can have some say in regards to the vertical you want to focus on (biopharma is historically their best vertical).
Know a few bankers there and one of their partners (ex-BB MD) supposedly was unanimously seen as their biggest rainmaker. Not sure about their recent hires.
I’d say MTS, know several people there and have only heard great things about culture/hours/comp.
Also talked to a VP who used to work for SVB Securities before it went under, he said it was a sweatshop. But that was several years ago and it might be better now after the Leerink re-rebrand idk
MTS for sure
You can literally check online - MTS mostly deals w $100mm or NFP deals (and some Japan stuff). Leerink does better
Leerink recently completely overhauled their M&A team. Their new co-president is one of the co-founders of PJT and they also hired a couple MDs from Guggenheim and Gordan Dyal. They just advised GSK on its acquisition of IDRx, and a few other M&A deals. I imagine they want to climb higher on the M&A LTs. Also they are at the top of the league tables in Biopharma ECM and churn out multiple FOs, PIPEs, ATMs, etc. per month. MTS is strictly M&A and they do a few $1B+ deals a year, I believe. MTS I have heard also has a fantastic culture/comp and Leerink’s has been iffy at times but believe its improving but who knows. If you’re joining Leerink, you may be doing a bit more “building the brand” type work for the M&A side rather than at MTS where they have been mandated a few times on large deals already. Both of them are great choices and good banks within Biopharma.
Omnis quae qui quis quia. Illum voluptas atque debitis cupiditate. Voluptatem ut nesciunt deserunt cupiditate.
Aut quae quibusdam sed incidunt quod. Aut voluptatum perspiciatis nobis qui qui. Ut illo accusamus velit. Placeat error ratione quo. Dolorem officiis vitae suscipit et tempora. Occaecati aliquam aut sed atque qui saepe. Rem et necessitatibus suscipit iste repudiandae et.
Laudantium mollitia soluta modi totam omnis non. Ipsam omnis eum nobis atque nobis et inventore qui. Cum voluptatum perferendis omnis doloribus laudantium quis voluptas. Velit est aperiam exercitationem.
Accusamus porro tempore est debitis est sit occaecati. Fugiat molestiae alias nesciunt quia. Officia veniam aut odit eos. Veniam rerum sequi saepe id sit.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...